Navigation Links
More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
Date:4/23/2008

e similar adverse effects.

Such effects may include: photosensitivity, pseudotumor cerebri, and

anti-anabolic action (which has led to increased BUN, azotemia,

acidosis, and hyperphosphatemia). As with tetracyclines, pancreatitis

has been reported with the use of TYGACIL

-- The safety and efficacy of TYGACIL in patients with hospital-acquired

pneumonia have not been established

-- In clinical trials, the most common treatment-emergent adverse events

in patients treated with TYGACIL were nausea (29.5%) and vomiting

(19.7%)

-- TYGACIL may cause fetal harm when administered to a pregnant woman

-- The safety and effectiveness of TYGACIL in patients below age 18 and

lactating women have not been established

-- Clostridium difficile-associated diarrhea (CDAD) has been reported with

use of nearly all antibacterial agents, including TYGACIL, and may

range in severity from mild diarrhea to fatal colitis

-- Concurrent use of antibacterial drugs with oral contraceptives may

render oral contraceptives less effective

-- The use of TYGACIL during tooth development may cause permanent

discoloration of the teeth. TYGACIL should not be used during tooth

development unless other drugs are not likely to be effective or are

contraindicated

-- Prothrombin time or other suitable anticoagulant test should be

monitored if TYGACIL is administered with warfarin

-- Monotherapy should be used with caution in patients with clinically

apparent intestinal perforation

-- In patients with severe hepatic impairment (Child Pugh C), the initial

dose of TYGACIL should be 100 mg followed by 25 mg every 12 hours.

Patients should be treated with caution and monitored for treatment

response

-- The following drugs should not be administered simultaneously through

th
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... LONDON , September 4, 2015 ... & Vaccines  Allergic Rhinitis drugs ... revenues Where is the market for allergic ... this market? Visiongain ,s new report shows you ... opportunities and prospects. Our 326 page report ...
(Date:9/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/gbd3bt/stability_testing ) ... of Pharmaceuticals (London, UK - December 2-3, 2015)" ... comprehensive two day seminar delegates will: - ... suitable for global arketing - Be able to ... and facilities - Know how to save resource ...
(Date:9/3/2015)... Report Details Ovarian Cancer ... Changes and Emerging Opportunities What,s the future for ... study forecasts those pharmaceutical revenues. There you find ... also explore trends, results, treatments, R&D, and opportunities, ... predictions to 2025 at overall world market, submarket, ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Stability Testing of Pharmaceuticals: 2 Day Seminar - London, UK - December 2-3, 2015 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 4Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 6
... Surgical Company (Nasdaq: STAA ) today announced that it will release ... Monday, November 2, 2009 after the market close. ... webcast on Tuesday, November 3, 2009 at 10:00 a.m. Eastern ... the Company,s third quarter results and current corporate developments. The timing ...
... SAN DIEGO, Oct. 27 Orexigen® Therapeutics, Inc. (Nasdaq: ... (ITT) analyses from the COR-I and COR-II Phase 3 trials ... stage Orexigen candidates for the treatment of obesity. These ... findings from a panel discussion on Saturday where the Company ...
Cached Medicine Technology:STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call 2Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 2Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 3Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 4Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 5Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 6
(Date:9/4/2015)... ... September 04, 2015 , ... ... personal humidifying medical devices, announced its only mission and research focus: Water Life ... Founder Sharon Kleyne, body water evaporation is becoming dangerously accelerated. As a result ...
(Date:9/4/2015)... ... 04, 2015 , ... The conference program for the upcoming ... 9-10, 2015 at the Diplomat Resort & Spa has been announced and is ... at the top of their field and will be presenting sessions such as ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... development of its first neighborhood created specifically for adults with intellectual, developmental and ... Phoenix Metro area and feature 30 cottage or “pocket” homes. In this community, ...
(Date:9/4/2015)... ... 04, 2015 , ... Steven Winter Associates, Inc., (SWA) is ... selected for the Residential Award of Merit by the Connecticut Green Building Council ... a highly competitive field of submissions, the net-zero energy residence will be honored ...
(Date:9/4/2015)... ... 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written ... the Pope’s upcoming trip to the United States. , Yisrayl lays out what he says ... Vatican and society is. Yisrayl also provides the meaning of his own name and describes ...
Breaking Medicine News(10 mins):Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... Vendormate nearly tripled its customer,base in 2008 and now ... the,U.S. in part because of economic uncertainty. Vendormate ... of supply chain,interruptions. , "With ... particular are anxious about their supply chain," said Andy,Monin, ...
... that the National Children,s Study will begin recruiting volunteers to take part ... affect children,s health. At a briefing, NIH officials announced that the first ... Carolina, and Queens, New York. , ... Washington, DC ...
... 13 Medarex, Inc. (Nasdaq: MEDX ... strong science-base and strategy for maximizing the value ... highlights of Medarex,s record of achievements in 2008, ... pipeline milestones in 2009, underscoring Medarex,s dedication to ...
... The Procter & Gamble Company (NYSE: PG ) ... the Common Stock and on the Series A and,Series B ... on,or after February 17, 2009 to shareholders of record at ... The company has been paying dividends without interruption ...
... Number One Cause of Death in Dogs Over 2MAF Canine Cancer Campaign ... owners and lovers in the United States view canine cancer as the ... One in four dogs die of cancer. Cancer is the ... Morris Animal Foundation (MAF) has posted on its ...
... DULUTH, Ga., Jan. 13 Metametrix Clinical Laboratory,( ... testing,services, announced the introduction of the new Fat-Soluble ... to measure a patient,s overall health,nutrient processing, and ... Fat-Soluble Vitamins Profile measures the following nutrients: , ...
Cached Medicine News:Health News:Economic Uncertainty Fuels Vendormate Growth in 2008 2Health News:National Children's Study Begins Recruiting Volunteers 2Health News:National Children's Study Begins Recruiting Volunteers 3Health News:National Children's Study Begins Recruiting Volunteers 4Health News:National Children's Study Begins Recruiting Volunteers 5Health News:Medarex Reviews Recent Highlights and Outlook for 2009 2Health News:Medarex Reviews Recent Highlights and Outlook for 2009 3Health News:Canine Cancer #1 Fear of Dog Lovers, Web Exclusive by Morris Animal Foundation Provides News on Latest Breakthroughs - Crucial Facts for Dog Owners 2Health News:Canine Cancer #1 Fear of Dog Lovers, Web Exclusive by Morris Animal Foundation Provides News on Latest Breakthroughs - Crucial Facts for Dog Owners 3Health News:Metametrix Introduces the New Fat-Soluble Vitamins Profile - A Snapshot of Overall Nutrition 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: